Alumis completed the merger with ACELYRIN in a $320m deal.

Alumis, a clinical-stage biopharmaceutical company, completed the merger with ACELYRIN, a late-stage clinical biopharma company, in a $320m deal. “We are excited to complete our merger and move forward with a significantly strengthened balance sheet to support Alumis’ differentiated late-stage portfolio and develop transformative therapies for patients. This merger allows us to advance our pipeline through multiple planned key data readouts, with a cash runway that now extends into 2027. We will remain disciplined across our operations and capital plan as we deliver on the significant benefits of the merger for our patients and stockholders alike," Martin Babler, Alumis President, CEO and Chairman.